The carcinoma-associated antigen EpCAM induces glyoxalase 1 resulting in enhanced methylglyoxal turnover

Cancer Genomics and Proteomics

Volumn 1, Issue 3, 2004, Pages 241-248

  Münz, Markus ^a   Hofmann, Tanja ^b   Scheibe, Burghardt ^c   Gänge, Matthias ^c   Junghanns, Kay T ^c   Zeidler, Reinhard ^d   Gires, Olivier ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Amersham Biosciences   (United States)

^d Vaecgene Biotech Inc   (Germany)

Author keywords

DIGE; EpCAM; Glyoxalase 1; Squamous cell carcinoma

Indexed keywords

EID: 16344376171     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Balzar M, Winter MJ, de Boer CJ and Litvinov SV: The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77: 699-712, 1999.
2. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren GJ and Warnaar SO: Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148: 865-75, 1996.
3. Riethmuller G, Schneider Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343: 1177-83, 1994.
4. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B and Lindhofer H: Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163: 1246-52, 1999.
5. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B and Lindhofer H: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83: 261-6, 2000.
6. Zaloudik J, Li W, Jacob L, Kieny MP, Somasundaram R, Acres B, Song H, Zhang T, Li J and Herlyn D: Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther 9: 382-9, 2002.
7. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA and Dreier T: In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100: 101-10, 2002.
8. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ and Warnaar SO: Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139: 1337-48, 1997.
9. Balzar M, Bakker HA, Briaire-de-Bruijn IH, Fleuren GJ, Warnaar SO and Litvinov SV: Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule. Mol Cell Biol 18: 4833-43, 1998.
10. Meyaard L, van der Vuurst de Vries AR, de Ruiter T, Lanier LL, Phillips JH and Clevers H: The epithelial cellular adhesion molecule (Ep-CAM) is a ligand for the leukocyteassociated immunoglobulin-like receptor (LAIR). J Exp Med 194: 107-12, 2001.
11. Pauli C, Munz M, Kieu C, Mack B, Breinl P, Wollenberg B, Lang S, Zeidler R and Gires O: Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett 193: 25-32, 2003.
12. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R and Gires O: The carcinoma associated antigen EpCAM up-regulates c-Myc and induces cell proliferation. Oncogene in press, 2004.
13. Oray B and Norton SJ: Glyoxalase I from mouse liver. Methods Enzymol 90 Pt E: 542-6, 1982.
14. Thornalley PJ: The glyoxalase system in health and disease. Mol Aspects Med 14: 287-371, 1993.
15. Mitsumoto A, Kim KR, Oshima G, Kunimoto M, Okawa K, Iwamatsu A and Nakagawa Y: Glyoxalase I is a novel nitricoxide-responsive protein. Biochem J 344 Pt 3: 837-44, 1999.
16. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG and Grizzle WE: Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 162: 1462-6, 1999.
17. Gastl G, Spizzo G, Obrist P, Dunser M and Mikuz G: Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981-2, 2000.
18. Spizzo G, Obrist P, Ensinger C, Theurl I, Dunser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G and Gastl G: Prognostic significance of Ep-CAM and Her-2/neu overexpression in invasive breast cancer. Int J Cancer 98: 883-8, 2002.
19. Kubuschok B, Passlick B, Izbicki JR, Thetter O and Pantel K: Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 17: 19-24, 1999.
20. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC and Grizzle WE: The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 31: 482-7, 2000.
21. Thornalley PJ: The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269: 1-11, 1990.
22. Phillips SA and Thornalley PJ: The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212: 101-5, 1993.
23. Richard JP: Mechanism for the formation of methylglyoxal from triosephosphates. Biochem Soc Trans 21: 549-53, 1993.
24. Thornalley PJ: Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27: 565-73, 1996.
25. Racker E and Spector M: Warburg effect revisited: merger of biochemistry and molecular biology. Science 213: 303-7, 1981.
26. Mearini E, Romani R, Mearini L, Antognelli C, Zucchi A, Baroni T, Porena M and Talesa VN: Differing expression of enzymes of the glyoxalase system in superficial and invasive bladder carcinomas. Eur J Cancer 38: 1946-50, 2002.
27. Davidson SD, Milanesa DM, Mallouh C, Choudhury MS, Tazaki H and Konno S: A possible regulatory role of glyoxalase I in cell viability of human prostate cancer. Urol Res 30: 116-21, 2002.
28. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC and Petricoin EF 3rd: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2: 76-84, 2002.
29. Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G and Talesa V: Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 66: 67-72, 2001.
30. Thornalley PJ: Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 31: 1372-7, 2003.
31. Creighton DJ, Zheng ZB, Holewinski R, Hamilton DS and Eiseman JL: Glyoxalase I inhibitors in cancer chemotherapy. Biochem Soc Trans 31: 1378-82, 2003.
32. Deswal R and Sopory SK: Glyoxalase I from Brassica juncea is a calmodulin stimulated protein. Biochim Biophys Acta 1450: 460-7, 1999.
33. Kim NS, Umezawa Y, Ohmura S and Kato S: Human glyoxalase I. cDNA cloning, expression, and sequence similarity to glyoxalase I from Pseudomonas putida. J Biol Chem 268: 11217-21, 1993.
34. Ranganathan S, Walsh ES, Godwin AK and Tew KD: Cloning and characterization of human colon glyoxalase-I. J Biol Chem 268: 5661-7, 1993.
35. Carrero-Valenzuela RD, Quan F, Lightowlers R, Kennaway NG, Litt M and Forte M: Human cytochrome c oxidase subunit VIb: characterization and mapping of a multigene family. Gene 102: 229-36, 1991.
36. Eller MS, Oleksiak MF, McQuaid TJ, McAfee SG and Gilchrest BA: The molecular cloning and expression of two CRABP cDNAs from human skin. Exp Cell Res 198: 328-36, 1992.
37. Kim TS, Sundaresh CS, Feinstein SI, Dodia C, Skach WR, Jain MK, Nagase T, Seki N, Ishikawa K, Nomura N and Fisher AB: Identification of a human cDNA clone for lysosomal type Ca2+-independent phospholipase A2 and properties of the expressed protein. J Biol Chem 272: 2542-50, 1997.